liarozole has been researched along with Disease Exacerbation in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bruynseels, J; de Porre, P; Debruyne, FM; Denis, L; Dijkman, GA; Fernandez del Moral, P | 1 |
| Boccardo, F; Brune, D; Bruynseels, J; De Porre, P; Debruyne, FJ; Denis, L; Fradet, Y; Janssens, M; Johansson, JE; Marberger, JM; Murray, R; Rassweiler, J; Tyrrell, C; Vangeneugden, T | 1 |
| Bruynseels, J; Crump, M; De Coster, R; Goel, R; Goss, PE; Nabholtz, JM; Oza, A; Reid, C; Tye, LM; Wadden, N | 1 |
| Abdolell, M; Blackstein, M; Clemons, M; Crump, M; De Coster, R; Goel, R; Goss, PE; Kaizer, L; Marques, R; Nabholtz, JM; Oza, A; Qi, S; Sterns, EE; Strasser, K | 1 |
4 trial(s) available for liarozole and Disease Exacerbation
| Article | Year |
|---|---|
Liarozole (R75251) in hormone-resistant prostate cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Disease Progression; Drug Resistance; Hormones; Humans; Imidazoles; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Treatment Outcome | 1997 |
Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Disease Progression; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate | 1998 |
Liarozole fumarate (R85246): a novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Estrogens; Female; Humans; Imidazoles; Middle Aged; Postmenopause; Quality of Life; Receptors, Estrogen; Skin Diseases | 2000 |
Liarozole fumarate (R85246): in the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estradiol; Female; Humans; Imidazoles; Mammary Neoplasms, Experimental; Middle Aged; Neoplasm Metastasis; Postmenopause; Quality of Life; Rats; Receptors, Estrogen; Tamoxifen; Treatment Outcome | 2000 |